Real-world use of brexpiprazole during inpatient treatment for schizophrenia: continuation, discontinuation, and concomitant psychotropics - Scorecard - MDSpire
Advertisement
Real-world use of brexpiprazole during inpatient treatment for schizophrenia: continuation, discontinuation, and concomitant psychotropics
Clinical Scorecard: Utilization of Brexpiprazole in Inpatient Schizophrenia Management: Patterns of Continuation, Discontinuation, and Use of Additional Psychotropic Medications
At a Glance
Category
Detail
Condition
Schizophrenia
Key Mechanisms
Serotonin-dopamine activity modulation; partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at 5-HT2A receptors.
Target Population
Inpatients with DSM-5 schizophrenia
Care Setting
Acute inpatient care
Key Highlights
53.7% continuation of brexpiprazole at week 8.
Common reasons for discontinuation included adverse events (32.3%) and insufficient efficacy (29.0%).
Female sex, lower prior chlorpromazine-equivalent dose, and shorter duration of untreated psychosis associated with continuation.
Guideline-Based Recommendations
Diagnosis
Utilize DSM-5 criteria for schizophrenia diagnosis.
Management
Consider brexpiprazole for acute symptom control and maintenance treatment.
Monitoring & Follow-up
Monitor for adverse events, particularly akathisia and efficacy.
Risks
Adverse events may lead to discontinuation; monitor for akathisia and insufficient efficacy.
Patient & Prescribing Data
Inpatients with acute schizophrenia treated with brexpiprazole.
Brexpiprazole shows potential for improved tolerability and treatment persistence.
Clinical Best Practices
Assess individual patient factors including illness severity and concomitant medications.
Prioritize agents with low sedative properties and lower risk of extrapyramidal effects.
